NFL Paying $1 Million to Fund Research Into Using Cannabis for Pain Relief
The investment comes after the league requested information about pain management alternatives to opioids in February
After putting out a formal request for information about pain management alternatives to opioids in February, the NFL and NFL Players Association are providing $1 million to fund research on cannabinoids and pain relief, according to Front Office Sports.
“While this represents a different stance by the league, it’s still conservative compared to players who use cannabis or cannabis products — particularly CBD, a non-psychoactive cannabinoid that has gained mainstream acceptance,” per FOS.
The NFL did shorten the window during which it tests players for THC and raise the threshold to trigger a positive test last season, but players can still be fined several weeks’ salary and be forced to join a treatment program for testing positive for the inhibiting chemical in marijuana. Though it shouldn’t be the case, that currently makes the use of CBD — which both past and current players swear by — somewhat of a grey area in the NFL.
In the February information request, the NFL-NFLPA’s pain management committee said it was looking for information including:
- The potential therapeutic role of medications and non-pharmacological interventions that are considered to be alternatives to opioids in routine pain management of NFL players. Medications may include, but are not limited to, cannabinoids such as cannabidiol (“CBD”).
- The impact of cannabis or cannabinoids on athletic performance in NFL players.
- The potential therapeutic role of medications and non-pharmacological interventions that are considered adjunctive to routine post-surgical orthopedic pain management in NFL football players.
Nothing is for certain, but it seems like a good assumption the new funding will be used to delve into some of the areas mentioned above.
“This isn’t an NFL or a sports issue; this is a societal issue,” the NFL’s chief medical officer Allen Sills told Bloomberg.
Thanks for reading InsideHook. Sign up for our daily newsletter and be in the know.
Suggested for you